TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Pharmaust Limited ( (AU:NUZ) ) has issued an announcement.
Neurizon Therapeutics Limited has secured $5 million through an institutional placement to support its strategic initiatives, including preparation for the HEALEY ALS Platform Trial and advancing pre-clinical programs. The funding strengthens Neurizon’s balance sheet and positions the company to further develop NUZ-001 for ALS and expand its potential across related neurodegenerative diseases, reflecting strong investor confidence and enhancing its industry positioning.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.52 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company is advancing its lead drug candidate, NUZ-001, for the treatment of ALS, the most common form of motor neurone disease. Neurizon aims to accelerate access to effective ALS treatments and explore the broader neurodegenerative applications of NUZ-001 through international collaborations and rigorous clinical programs.
Average Trading Volume: 305,562
Technical Sentiment Signal: Sell
Current Market Cap: A$68.92M
See more data about NUZ stock on TipRanks’ Stock Analysis page.